This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
1 Primary · 3 Secondary · Reporting Duration: 8-year estimates, reported at a median follow-up of 8 years
Active Control
Experimental Treatment
3066 Total Participants · 3 Treatment Groups
Primary Treatment: Quality-of-Life Assessment · No Placebo Group · Phase 3
Age 18 - 65 · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: